Spark Therapeutics Company Profile (NASDAQ:ONCE)

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONCE
  • CUSIP: N/A
  • Web: www.sparktx.com
Capitalization:
  • Market Cap: $1.65 billion
  • Outstanding Shares: 31,128,000
Average Prices:
  • 50 Day Moving Avg: $55.49
  • 200 Day Moving Avg: $56.66
  • 52 Week Range: $35.07 - $65.99
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.96
  • P/E Growth: -0.44
Sales & Book Value:
  • Annual Revenue: $20.17 million
  • Price / Sales: 81.78
  • Book Value: $9.32 per share
  • Price / Book: 5.69
Profitability:
  • EBIDTA: ($137,080,000.00)
  • Net Margins: -441.05%
  • Return on Equity: -28.28%
  • Return on Assets: -25.39%
Debt:
  • Current Ratio: 12.83%
  • Quick Ratio: 12.83%
Misc:
  • Average Volume: 267,387 shs.
  • Beta: 3.51
  • Short Ratio: 12.66
 

Frequently Asked Questions for Spark Therapeutics (NASDAQ:ONCE)

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics Inc (NASDAQ:ONCE) released its earnings results on Tuesday, May, 9th. The company reported ($1.70) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.36) by $0.34. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1.35 million. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The firm's quarterly revenue was down 1.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.95) EPS. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

12 equities research analysts have issued twelve-month price objectives for Spark Therapeutics' shares. Their forecasts range from $28.00 to $94.00. On average, they expect Spark Therapeutics' share price to reach $68.86 in the next twelve months. View Analyst Ratings for Spark Therapeutics.

What are analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (5/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
  • 3. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Who are some of Spark Therapeutics' key competitors?

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Who owns Spark Therapeutics stock?

Spark Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), BlackRock Inc. (5.93%), Vanguard Group Inc. (5.89%), JPMorgan Chase & Co. (4.99%), State Street Corp (2.84%) and Wellington Management Group LLP (2.61%). Company insiders that own Spark Therapeutics stock include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High, Stephen W Webster and Steven Altschuler. View Institutional Ownership Trends for Spark Therapeutics.

Who sold Spark Therapeutics stock? Who is selling Spark Therapeutics stock?

Spark Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Sofinnova Management VIII L.L.C., Pictet Asset Management Ltd., UBS Group AG, Morgan Stanley, State Street Corp, C WorldWide Group Holding A S and Endurant Capital Management LP. Company insiders that have sold Spark Therapeutics stock in the last year include Anand Mehra, Barge Joseph La, Coelho Rogerio Vivaldi, Hospital Of Philade Children's, Jeffrey D Marrazzo, Katherine A High and Stephen W Webster. View Insider Buying and Selling for Spark Therapeutics.

Who bought Spark Therapeutics stock? Who is buying Spark Therapeutics stock?

Spark Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Wellington Management Group LLP, Wells Fargo & Company MN, JPMorgan Chase & Co., Vanguard Group Inc., Janus Capital Management LLC, Victory Capital Management Inc. and FMR LLC. View Insider Buying and Selling for Spark Therapeutics.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Spark Therapeutics stock cost?

One share of Spark Therapeutics stock can currently be purchased for approximately $52.99.

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (?)
Ratings Breakdown: 2 Sell Ratings, 2 Hold Ratings, 8 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $68.86 (29.96% upside)

Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/20/2017ValuEngineDowngradeHold -> SellLowView Rating Details
5/10/2017WedbushReiterated RatingUnderperform$28.00MediumView Rating Details
5/9/2017Cantor FitzgeraldSet Price TargetBuy$94.00MediumView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingHold$59.00LowView Rating Details
4/10/2017Stifel NicolausReiterated RatingBuy$76.00LowView Rating Details
4/7/2017BMO Capital MarketsReiterated RatingOutperform$69.00LowView Rating Details
2/22/2017Cowen and CompanySet Price TargetBuy$75.00N/AView Rating Details
2/22/2017JPMorgan Chase & Co.Set Price TargetBuy$82.00N/AView Rating Details
2/9/2017Leerink SwannInitiated CoverageOutperform -> Outperform$85.00N/AView Rating Details
12/6/2016Chardan CapitalReiterated RatingNeutralN/AView Rating Details
7/12/2016Royal Bank of CanadaInitiated CoverageOutperform$70.00N/AView Rating Details
6/21/2016SunTrust Banks, Inc.Boost Price TargetBuy$64.00 -> $72.00N/AView Rating Details
4/12/2016Evercore ISIInitiated CoverageBuy$37.00N/AView Rating Details
3/30/2016Goldman Sachs Group IncInitiated CoverageBuy -> Neutral$44.00N/AView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldN/AView Rating Details
10/11/2015Roth CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Spark Therapeutics (NASDAQ:ONCE)
Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Earnings History by Quarter for Spark Therapeutics (NASDAQ:ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
2017 EPS Consensus Estimate: ($6.37)
2018 EPS Consensus Estimate: ($5.86)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.75)($1.32)($1.44)
Q2 20174($1.77)($1.36)($1.64)
Q3 20174($1.80)($1.37)($1.66)
Q4 20174($1.77)($1.27)($1.63)
Q1 20181($1.67)($1.67)($1.67)
Q2 20181($1.43)($1.43)($1.43)
Q3 20181($1.40)($1.40)($1.40)
Q4 20181($1.36)($1.36)($1.36)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Spark Therapeutics (NASDAQ:ONCE)
Insider Ownership Percentage: 9.60%
Institutional Ownership Percentage: 83.97%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.00View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.00View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.00View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.00View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Spark Therapeutics (NASDAQ:ONCE)
Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
Source:
DateHeadline
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Expected to Post Earnings of -$1.75 Per Share
www.americanbankingnews.com - May 26 at 7:37 AM
finance.yahoo.com logoETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 5:33 AM
finance.yahoo.com logoETFs with exposure to Spark Therapeutics, Inc. : May 25, 2017
finance.yahoo.com - May 26 at 5:33 AM
finance.yahoo.com logoSpark Therapeutics, Inc. :ONCE-US: Earnings Analysis: Q1, 2017 By the Numbers : May 24, 2017
finance.yahoo.com - May 24 at 7:15 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 23 at 2:20 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 21 at 8:02 PM
bizjournals.com logoSpark completes FDA application for gene therapy candidate to repair vision loss - Philadelphia Business Journal
www.bizjournals.com - May 20 at 11:38 PM
finance.yahoo.com logoSpark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene Neparvovec
finance.yahoo.com - May 19 at 11:50 AM
finance.yahoo.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : ONCE-US : May 18, 2017
finance.yahoo.com - May 19 at 11:50 AM
finance.yahoo.com logoSpark completes FDA application for gene therapy candidate to repair vision loss
finance.yahoo.com - May 19 at 11:50 AM
americanbankingnews.com logoCantor Fitzgerald Equities Analysts Reduce Earnings Estimates for Spark Therapeutics Inc (ONCE)
www.americanbankingnews.com - May 15 at 8:40 AM
americanbankingnews.com logoWedbush Equities Analysts Raise Earnings Estimates for Spark Therapeutics Inc (ONCE)
www.americanbankingnews.com - May 12 at 8:51 AM
americanbankingnews.com logoAnalysts Set Expectations for Spark Therapeutics Inc's Q2 2017 Earnings (ONCE)
www.americanbankingnews.com - May 12 at 8:50 AM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Expected to Earn Q2 2017 Earnings of ($1.71) Per Share
www.americanbankingnews.com - May 12 at 8:50 AM
nasdaq.com logoCommit To Purchase Spark Therapeutics At $50, Earn 25.9% Annualized Using Options - Nasdaq
www.nasdaq.com - May 11 at 7:31 PM
americanbankingnews.com logoAnalysts Set Expectations for Spark Therapeutics Inc's FY2021 Earnings (ONCE)
www.americanbankingnews.com - May 11 at 3:58 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Forecasted to Post Q1 2018 Earnings of ($1.67) Per Share
www.americanbankingnews.com - May 11 at 1:30 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:26 AM
finance.yahoo.com logoEdited Transcript of ONCE earnings conference call or presentation 9-May-17 12:30pm GMT
finance.yahoo.com - May 10 at 11:53 AM
americanbankingnews.com logoSpark Therapeutics' (ONCE) Underperform Rating Reiterated at Wedbush
www.americanbankingnews.com - May 10 at 9:20 AM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Given a $94.00 Price Target by Cantor Fitzgerald Analysts
www.americanbankingnews.com - May 9 at 11:36 PM
seekingalpha.com logoSpark's (ONCE) CEO Jeff Marrazzo on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 6:37 PM
finance.yahoo.com logoSpark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress
finance.yahoo.com - May 9 at 11:19 AM
finance.yahoo.com logoSpark Therapeutics reports 1Q loss
finance.yahoo.com - May 9 at 11:19 AM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 9 at 10:22 AM
americanbankingnews.com logoSpark Therapeutics (ONCE) Receiving Positive News Coverage, Report Finds
www.americanbankingnews.com - May 4 at 11:17 AM
americanbankingnews.com logo Analysts Anticipate Spark Therapeutics Inc (ONCE) Will Announce Quarterly Sales of $4.75 Million
www.americanbankingnews.com - May 4 at 10:56 AM
finance.yahoo.com logoSpark Therapeutics to Participate in Multiple Meetings in May
finance.yahoo.com - May 3 at 8:00 PM
americanbankingnews.com logo-$1.36 Earnings Per Share Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - May 3 at 12:04 AM
globenewswire.com logoSpark Therapeutics to Host Conference Call on Tuesday, May 9 at 8:30 a.m. to Discuss Q1 2017 Results - GlobeNewswire (press release)
globenewswire.com - May 2 at 11:11 AM
finance.yahoo.com logoSpark Therapeutics to Host Conference Call on Tuesday, May 9 at 8:30 a.m. to Discuss Q1 2017 Results
finance.yahoo.com - May 2 at 11:11 AM
americanbankingnews.com logoSpark Therapeutics (ONCE) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - May 1 at 5:34 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) to Release Earnings on Tuesday
www.americanbankingnews.com - April 30 at 9:10 AM
americanbankingnews.com logoSpark Therapeutics (ONCE) Given Daily News Sentiment Rating of 0.17
www.americanbankingnews.com - April 28 at 11:40 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 28 at 4:28 PM
finance.yahoo.com logoSpark Therapeutics, Inc. – Value Analysis (NASDAQ:ONCE) : April 27, 2017
finance.yahoo.com - April 27 at 7:31 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) CFO Stephen W. Webster Sells 1,898 Shares
www.americanbankingnews.com - April 26 at 11:38 PM
americanbankingnews.com logoInsider Selling: Spark Therapeutics Inc (ONCE) Insider Sells 2,060 Shares of Stock
www.americanbankingnews.com - April 26 at 11:36 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) CFO Stephen W. Webster Sells 10,000 Shares
www.americanbankingnews.com - April 26 at 8:40 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Insider Katherine A. High Sells 15,000 Shares
www.americanbankingnews.com - April 26 at 8:22 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - April 26 at 6:24 PM
finance.yahoo.com logoSpark Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : ONCE-US : April 26, 2017
finance.yahoo.com - April 26 at 6:14 PM
americanbankingnews.com logoSpark Therapeutics (ONCE) Getting Somewhat Positive Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 8:00 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Short Interest Down 1.6% in March
www.americanbankingnews.com - April 24 at 5:54 PM
americanbankingnews.com logoSpark Therapeutics (ONCE) Receives Daily Coverage Optimism Score of -0.14
www.americanbankingnews.com - April 18 at 9:57 AM
americanbankingnews.com logoSpark Therapeutics (ONCE) Receives Daily Coverage Optimism Score of 0.39
www.americanbankingnews.com - April 13 at 3:32 PM
americanbankingnews.com logo$4.06 Million in Sales Expected for Spark Therapeutics Inc (ONCE) This Quarter
www.americanbankingnews.com - April 13 at 11:32 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Spark Therapeutics Inc (ONCE) to Announce -$1.36 Earnings Per Share
www.americanbankingnews.com - April 11 at 6:06 PM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Downgraded to "Hold" at Vetr Inc.
www.americanbankingnews.com - April 11 at 12:51 AM
americanbankingnews.com logoSpark Therapeutics Inc (ONCE) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 10 at 2:08 PM

Social

Chart

Spark Therapeutics (ONCE) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff